Quick Answer
AN2 Therapeutics, Inc. reported R&D Expense of $24.77 million for fiscal year 2025.
AN2 Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $24.77M | -38.8% |
| 2024 | $40.49M | -26.2% |
| 2023 | $54.87M | +92.5% |
| 2022 | $28.51M | +76.5% |
| 2021 | $16.16M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.00M | -15.5% | +118.8% |
| June 30, 2025 | $3.20M | -73.7% | -58.4% |
| March 31, 2025 | $7.69M | -47.5% | -7.2% |
| September 30, 2024 | $8.29M | -42.6% | -31.8% |
| June 30, 2024 | $12.15M | -10.3% | -17.1% |
| March 31, 2024 | $14.65M | +22.3% | +1.6% |
| September 30, 2023 | $14.43M | +94.3% | +6.6% |
| June 30, 2023 | $13.54M | +102.1% | +13.0% |
- AN2 Therapeutics, Inc. showed a decrease of -38.8% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, AN2 Therapeutics, Inc.’s r&d expense has grown by 53.3% (from $16.16 million to $24.77 million).
- The most recent figure is from AN2 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: